{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=20", "query": { "intervention": "Injectable Placebo", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 4205, "total_pages": 421, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T12:50:22.625Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03541499", "title": "Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pertussis", "Pertussis Immunisation" ], "interventions": [ { "name": "BPZE1", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 50, "start_date": "2018-10-23", "completion_date": "2020-05-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541499" }, { "nct_id": "NCT07118449", "title": "Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Artery Disease (CAD)" ], "interventions": [ { "name": "XC001", "type": "DRUG" }, { "name": "A195/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XyloCor Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 116, "start_date": "2025-08-27", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07118449" }, { "nct_id": "NCT03720470", "title": "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis", "Dermatitis, Atopic", "Eczema", "Skin Diseases", "Skin Diseases, Genetic", "Genetic Diseases, Inborn", "Skin Diseases, Eczematous", "Hypersensitivity", "Hypersensitivity, Immediate", "Immune System Diseases" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" }, { "name": "Injectable Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2018-10-29", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03720470" }, { "nct_id": "NCT02762929", "title": "Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postoperative Pain", "Bunions" ], "interventions": [ { "name": "HTX-011A", "type": "DRUG" }, { "name": "Saline Placebo", "type": "BIOLOGICAL" }, { "name": "HTX-011B", "type": "DRUG" }, { "name": "HTX-002", "type": "DRUG" }, { "name": "Bupivacaine HCl", "type": "DRUG" }, { "name": "HTX-009", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Heron Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2016-05", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 5, "location_summary": "Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Pasadena", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02762929" }, { "nct_id": "NCT05891587", "title": "Semaglutide Therapy for Alcohol Reduction - Tulsa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oklahoma State University Center for Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2023-07-07", "completion_date": "2025-10-01", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891587" }, { "nct_id": "NCT01194414", "title": "A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tocilizumab SC", "type": "DRUG" }, { "name": "tocilizumab IV", "type": "DRUG" }, { "name": "placebo to tocilizumab SC", "type": "DRUG" }, { "name": "placebo to tocilizumab IV", "type": "DRUG" }, { "name": "Disease-modifying antirheumatic drugs (DMARDs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1262, "start_date": "2010-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-06-20", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 54, "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194414" }, { "nct_id": "NCT03681184", "title": "A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Hyperoxaluria Type 1 (PH1)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Lumasiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 39, "start_date": "2018-11-27", "completion_date": "2024-01-12", "has_results": true, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 5, "location_summary": "San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03681184" }, { "nct_id": "NCT01227044", "title": "Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Reduction in Heavy Drinking in Patients With HIV" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo + Medication Management/Medication Coaching", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2011-04", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 2, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227044" }, { "nct_id": "NCT04568434", "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2020-11-18", "completion_date": "2023-10-17", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 17, "location_summary": "Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04568434" }, { "nct_id": "NCT03331965", "title": "Metoclopramide Versus Placebo for GJ Placement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Radiation Exposure", "Enteral Nutrition" ], "interventions": [ { "name": "Metoclopramide 5 MG/ML Injectable Solution", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2018-04-09", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-10-18T12:50:22.625Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03331965" } ] }